65 results about "Thymosin α1" patented technology

A method for overcoming immune suppression includes the steps of inducing production of naïve T cells and restoring T cell immunity. A method of vaccine immunotherapy includes the steps of inducing production of naïve T cells and exposing the naïve T cells to endogenous or exogenous antigens at an appropriate site. Additionally, a method for unblocking immunization at a regional lymph node includes the steps of promoting differentiation and maturation of immature dendritic cells at a regional lymph node and allowing presentation of processed peptides by resulting mature dendritic cells, thus, for example, exposing tumor peptides to T cells to gain immunization of the T cells. Further, a method of treating cancer and other persistent lesions includes the steps of administering an effective amount of a natural cytokine mixture as an adjuvant to endogenous or exogenous administered antigen to the cancer or other persistent lesions; preferably the natural cytokine mixture is administered in combination with thymosin α1.

The invention discloses a chemically modified thymulin alpha 1 and a synthetic method thereof. The structure of the chemically modified thymulin alpha 1 is shown as follows: A-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-IIe-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH or Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-IIe-Thr-Thr-Lys(A)-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH. The A is an aliphatic acid bonding in affinity with human serum albumin, or is a maleimide derivative coupled with free sulfydryl of human serum albumin. The chemically modified thymulin alpha 1 has characteristics of precision modification sites, a definite chemical structure and a simple and concise synthetic process. The chemically modified thymulin alpha 1 after being injected intravenously bonds immediately with the serum albumin of the human body and adopts the serum albumin of the human body as a controlled-release vector, thus prolonging the half-life period largely, and significantly prolonging the time of duration of the effective medicine concentration. The bioavailability is high.

The invention discloses a method and special engineering bacteria for producing N-terminal acetyl protein or polypeptide. The recombinant engineering bacteria capable of expressing transferase of archaebacteria on chromosomes are obtained by integrating the expression box of the transferase of archaebacteria onto the chromosomes of a host; the expression box for expressing the transferase of archaebacteria comprises a promoter and an archaebacteria transferase gene connected with the downstream of the promoter; and the nucleotide sequence of the archaebacteria transferase gene is represented by the sequence No.1 in a sequence list, and the amino acid sequence of the archaebacteria transferase gene is represented by a sequence No.2 in a sequence table. The engineering bacteria of the invention can directly produce complete N-terminal acetyl protein or polypeptide, such as thymosin extrasin alpha 1 and thymosin extrasin beta 4, the drawback of incompetence of acetylation or partial acetylation in a conventional genetic engineering technique is overcome, the production of N-terminal acetyl thymosin extrasin by the genetic engineering technique is realized completely, and the method and the special engineering bacteria are very practical.

The invention provides a method for preparing thymosin alpha 1 by liquid phase fragment condensation, belonging to the technical field of biochemistry. According to the method, high capacity value (not less than 0.8mmol / g) resin is used as a starting material, firstly, a standard solid phase polypeptide synthesis (SPPS) technology is adopted for synthesizing a high-purity peptide fragments with selected structures, then, a liquid phase condensation technology is adopted for connecting the peptide fragments, and thus, a high-purity (more than 99%) target peptide is obtained. Compared with the solid phase thymosin alpha 1 synthesis technology, the method provided by the invention avoids the problem of low coupling ratio of amino acids behind the 12th position, and greatly improves yield (up to 25-30%) of the thymosin alpha 1; meanwhile, the peptide fragment formed by solid phase synthesis is free from purification, post-treatment technology is simplified, finally, the thymosin alpha 1 is purified by means of high performance liquid chromatography, preparation difficulty is reduced, preparation times is decreased, synthesis cost of the thymosin alpha 1 is lowered, and implementation of large-scale and industrialized production is facilitated.

The present invention relates to the field of medicinal bioengineering technology and is a recombinant thymin alpha-1, that is Gly-T alpha-1, and its preparation method. The gene engineering process to prepare Gly-T alpha-1 includes PCR to amplify gene segment with 5'-GGGGATCCGACGCAGCCGTAGAC-3' as upstream primer, 5'-GGGAATTCTTATTTTCTGCCTCTTCCAC-3' as downstream primer and human placenta CDNA as template, EcoRI / BamHI double enzyme incision for directional cloning of destination gene to pGEX-4T-1 to constitue fused expression vector pGEX-4T-1 / T alpha-1. The prepared engineering bacterium can express glutathion S-transferase- thymin alpha-1 fusion protein and affinity chromatography purified fusion protein, and thrombase incision releases Gly-T alpha-1, which is finally purified by the affinity chromatography and ion exchange chromatography.